Showing results (291-300 of 323) with videos related to

Sort By:
Pageof 33
Biorxiv : the Preprint Server for Biology|December 18, 2023
Rapid modeling of an ultra-rare epilepsy variant in wild-type mice by in utero prime editingColin D Robertson, Patrick Davis, Ryan R Richardson, et al.
The Lancet. Oncology|March 29, 2012
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialVincent A Miller, Vera Hirsh, Jacques Cadranel, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2017
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteriaLeena Gandhi, Sai-Hong Ignatius Ou, Alice T Shaw, et al.
Frontiers in Cellular Neuroscience|May 28, 2020
Multimodal Analysis of STRADA Function in Brain DevelopmentLouis T Dang, Katarzyna M Glanowska, Philip H Iffland Ii, et al.
Annals of Clinical and Translational Neurology|May 23, 2015
Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5Thomas Scerri, Jessica R Riseley, Greta Gillies, et al.
Progress in Cardiovascular Diseases|January 22, 2024
RNA in cardiovascular disease: A new frontier of personalized medicineToufik Abdul-Rahman, Ileana Lizano-Jubert, Zarah Sophia Blake Bliss, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung CancerJames Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.
Annals of Neurology|August 19, 2015
Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3Joe C Sim, Thomas Scerri, Miriam Fanjul-Fernández, et al.
Pageof 33